PL2601949T3 - Kompozycje farmaceutyczne z (1S)-1,5-anhydro-1-[5-(4-etoksybenzylo)-2-metoksy-4-metylofenylo]-1-tio-D-glucitolem oraz substancją zwiększającą wydzielanie insuliny - Google Patents

Kompozycje farmaceutyczne z (1S)-1,5-anhydro-1-[5-(4-etoksybenzylo)-2-metoksy-4-metylofenylo]-1-tio-D-glucitolem oraz substancją zwiększającą wydzielanie insuliny

Info

Publication number
PL2601949T3
PL2601949T3 PL13157571T PL13157571T PL2601949T3 PL 2601949 T3 PL2601949 T3 PL 2601949T3 PL 13157571 T PL13157571 T PL 13157571T PL 13157571 T PL13157571 T PL 13157571T PL 2601949 T3 PL2601949 T3 PL 2601949T3
Authority
PL
Poland
Prior art keywords
ethoxybenzyl
glucitol
anhydro
thio
methylphenyl
Prior art date
Application number
PL13157571T
Other languages
English (en)
Inventor
Teisuke Takahashi
Saeko Uchida
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of PL2601949T3 publication Critical patent/PL2601949T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL13157571T 2009-04-16 2010-04-16 Kompozycje farmaceutyczne z (1S)-1,5-anhydro-1-[5-(4-etoksybenzylo)-2-metoksy-4-metylofenylo]-1-tio-D-glucitolem oraz substancją zwiększającą wydzielanie insuliny PL2601949T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009100210 2009-04-16
EP10764570.7A EP2419097B1 (en) 2009-04-16 2010-04-16 Pharmaceutical composition comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes
EP13157571.4A EP2601949B1 (en) 2009-04-16 2010-04-16 Pharmaceutical compositions with (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol and an insulin secretagogue.

Publications (1)

Publication Number Publication Date
PL2601949T3 true PL2601949T3 (pl) 2015-04-30

Family

ID=42982643

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13157571T PL2601949T3 (pl) 2009-04-16 2010-04-16 Kompozycje farmaceutyczne z (1S)-1,5-anhydro-1-[5-(4-etoksybenzylo)-2-metoksy-4-metylofenylo]-1-tio-D-glucitolem oraz substancją zwiększającą wydzielanie insuliny
PL10764570T PL2419097T3 (pl) 2009-04-16 2010-04-16 Kompozycja farmaceutyczna zawierająca (1S)-1,5-anhydro-1-[5-(4-etoksybenzylo)-2-metoksy-4-metylofenylo]-1-tio-D-glucitol i metforminę oraz jej zastosowanie w leczeniu cukrzycy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL10764570T PL2419097T3 (pl) 2009-04-16 2010-04-16 Kompozycja farmaceutyczna zawierająca (1S)-1,5-anhydro-1-[5-(4-etoksybenzylo)-2-metoksy-4-metylofenylo]-1-tio-D-glucitol i metforminę oraz jej zastosowanie w leczeniu cukrzycy

Country Status (30)

Country Link
US (1) US20120040898A1 (pl)
EP (3) EP2601949B1 (pl)
JP (4) JP5077786B2 (pl)
KR (2) KR20150046382A (pl)
CN (7) CN105343880A (pl)
AR (1) AR076317A1 (pl)
AU (1) AU2010237748B2 (pl)
BR (1) BRPI1012539A2 (pl)
CA (1) CA2755392A1 (pl)
CY (2) CY1114703T1 (pl)
DK (2) DK2601949T3 (pl)
ES (2) ES2431300T3 (pl)
HK (6) HK1217302A1 (pl)
HR (2) HRP20131120T1 (pl)
ME (2) ME01555B (pl)
MX (1) MX2011010901A (pl)
MY (3) MY182720A (pl)
NZ (4) NZ595314A (pl)
PH (3) PH12015500235B1 (pl)
PL (2) PL2601949T3 (pl)
PT (2) PT2419097E (pl)
RS (2) RS53761B1 (pl)
RU (2) RU2532330C2 (pl)
SG (6) SG2014012462A (pl)
SI (2) SI2419097T1 (pl)
SM (1) SMT201500015B (pl)
TW (3) TW201103534A (pl)
UA (2) UA105216C2 (pl)
WO (1) WO2010119990A1 (pl)
ZA (1) ZA201106727B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
EP2486029B1 (en) 2009-09-30 2015-06-10 Boehringer Ingelheim International GmbH Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
US20120283169A1 (en) * 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201101809A1 (tr) * 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
MX360304B (es) 2012-05-17 2018-10-29 Vtv Therapeutics Llc Composiciones de activador de glucocinasa para el tratamiento de la diabetes.
SG11201501510SA (en) * 2012-08-30 2015-04-29 Taisho Pharmaceutical Co Ltd Combinations of sglt2 inhibitors and antihypertensive drugs
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201901110T4 (tr) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Empagliflozinin terapötik kullanımları.
SI2986304T1 (sl) 2013-04-18 2022-04-29 Boehringer Ingelheim International Gmbh Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe
TW201513857A (zh) * 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
EP3263134B1 (en) * 2015-02-27 2021-05-05 The Asan Foundation Composition for preventing or treating valve calcification, containing dpp-4 inhibitor
CN105963280B (zh) * 2016-06-30 2018-11-06 合肥华方医药科技有限公司 一种伏格列波糖口腔速溶膜及其制备方法
CN109843279A (zh) 2016-10-19 2019-06-04 勃林格殷格翰国际有限公司 包含ssao/vap-1抑制剂和sglt2抑制剂的药物组合、其用途
CN110168098A (zh) * 2016-11-14 2019-08-23 高雄医学大学 一种检测糖代谢异常的方法及其预防及治疗
EP3781166A1 (en) 2018-04-17 2021-02-24 Boehringer Ingelheim International GmbH Pharmaceutical composition, methods for treating and uses thereof
KR20190137343A (ko) 2018-06-01 2019-12-11 김유찬 계량 인덕션
JP2021526130A (ja) 2018-06-12 2021-09-30 ブイティーブイ・セラピューティクス・エルエルシー インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
JP2003520759A (ja) 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド 単位核を有する徐放性錠剤
WO2002080936A1 (en) * 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
AU2002254567B2 (en) * 2001-04-11 2007-10-11 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
JP5152519B2 (ja) * 2006-06-29 2013-02-27 大正製薬株式会社 C−フェニル1−チオグルシト−ル化合物
JP5194588B2 (ja) * 2006-07-06 2013-05-08 大正製薬株式会社 1−チオ−d−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤
US8039441B2 (en) * 2006-08-15 2011-10-18 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
BRPI0718596B8 (pt) * 2006-11-09 2021-05-25 Boehringer Ingelheim Int composições farmacêuticas para terapia de combinação com inibidores de sglt-2 e metformina
AU2007332476A1 (en) * 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. 1-phenyl 1-thio-D-glucitol derivative
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
CL2008002425A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.

Also Published As

Publication number Publication date
RS53761B1 (en) 2015-06-30
AU2010237748A1 (en) 2011-10-20
HK1217301A1 (zh) 2017-01-06
MY182720A (en) 2021-02-03
CN105343880A (zh) 2016-02-24
AR076317A1 (es) 2011-06-01
RU2011146335A (ru) 2013-05-27
NZ606888A (en) 2014-07-25
TW201622720A (zh) 2016-07-01
ES2523408T3 (es) 2014-11-25
HK1217434A1 (zh) 2017-01-13
CY1114703T1 (el) 2016-10-05
ZA201106727B (en) 2012-11-28
SG2014012553A (en) 2014-05-29
HK1217302A1 (zh) 2017-01-06
SG2014014807A (en) 2014-05-29
JP2015063543A (ja) 2015-04-09
EP2829271A2 (en) 2015-01-28
HRP20141080T1 (hr) 2015-01-02
PT2601949E (pt) 2014-11-12
EP2419097B1 (en) 2013-09-25
PL2419097T3 (pl) 2014-02-28
TW201500043A (zh) 2015-01-01
EP2601949A3 (en) 2013-09-18
ES2431300T3 (es) 2013-11-25
WO2010119990A1 (en) 2010-10-21
HK1218871A1 (zh) 2017-03-17
KR20150046382A (ko) 2015-04-29
JP2012524710A (ja) 2012-10-18
CN105477639A (zh) 2016-04-13
PH12019500959A1 (en) 2020-06-29
PH12019500959B1 (en) 2020-06-29
EP2419097A4 (en) 2012-09-05
CN105343059A (zh) 2016-02-24
KR20120016051A (ko) 2012-02-22
SI2419097T1 (sl) 2014-01-31
PH12019500961A1 (en) 2020-08-03
PH12019500961B1 (en) 2020-08-03
CN105343060A (zh) 2016-02-24
SG2014012462A (en) 2014-05-29
NZ623838A (en) 2015-09-25
HK1217435A1 (zh) 2017-01-13
HRP20131120T1 (hr) 2013-12-20
MY156679A (en) 2016-03-15
MX2011010901A (es) 2011-11-01
CN102395364A (zh) 2012-03-28
UA111742C2 (uk) 2016-06-10
CY1115907T1 (el) 2017-01-25
SG2014015093A (en) 2014-04-28
SI2601949T1 (sl) 2014-12-31
NZ595314A (en) 2013-03-28
DK2601949T3 (da) 2015-01-05
RU2532330C2 (ru) 2014-11-10
PH12015500235A1 (en) 2015-12-02
EP2419097A1 (en) 2012-02-22
EP2829271A3 (en) 2015-05-27
EP2601949B1 (en) 2014-10-29
ME01555B (me) 2014-04-20
AU2010237748B2 (en) 2014-10-30
SG2014012405A (en) 2014-05-29
CN105343871A (zh) 2016-02-24
RS53056B (en) 2014-04-30
CA2755392A1 (en) 2010-10-21
DK2419097T3 (da) 2013-10-28
MY183793A (en) 2021-03-16
SMT201500015B (it) 2015-03-05
BRPI1012539A2 (pt) 2016-03-29
TW201103534A (en) 2011-02-01
EP2601949A2 (en) 2013-06-12
CN105434430A (zh) 2016-03-30
SG175154A1 (en) 2011-11-28
JP2013006854A (ja) 2013-01-10
NZ710575A (en) 2016-06-24
US20120040898A1 (en) 2012-02-16
JP6066144B2 (ja) 2017-01-25
UA105216C2 (en) 2014-04-25
ME02015B (me) 2015-05-20
JP5660094B2 (ja) 2015-01-28
HK1218881A1 (zh) 2017-03-17
JP5910711B2 (ja) 2016-04-27
JP2016104775A (ja) 2016-06-09
JP5077786B2 (ja) 2012-11-21
PT2419097E (pt) 2013-10-03
RU2014121260A (ru) 2015-12-10
PH12015500235B1 (en) 2015-12-02

Similar Documents

Publication Publication Date Title
PT2601949E (pt) Composições farmacêuticas com (1s)-1,5-anidro-1-[5-(4- etoxibenzil)-2-metoxi-4-metilfenil]-1-tio-d-glucitol e um secretagogo de insulina
HUS1700023I1 (hu) GLP-1 agonistát, inzulint és metionint tartalmazó gyógyászati készítmény
BRPI1012892A2 (pt) composto, e, composição farmacêutica.
EP2499195A4 (en) Oxygen scavengers, compositions comprising the scavengers, and artcles made from the compositions
AP2011005821A0 (en) Processing biomas.
IL216254A (en) Compounds, pharmaceutical compositions and their uses
IL220509A (en) Compressed pyridinylpyrolidone, a pharmaceutical preparation and combination
AP2011005754A0 (en) Processing biomas.
ZA201006126B (en) Protease stabilized, acylated insulin analogues
AP2010005383A0 (en) Densified fuel pellets.
IL220284A0 (en) Insulin analogues with chlorinated amino acids, compositions comprising the same and uses thereof
EP2447334A4 (en) CONNECTION FOR AN ORGANIC PHOTOELECTRIC ELEMENT AND ORGANIC PHOTOELECTRIC ELEMENT THEREWITH
EP2455123A4 (en) Piston for syringe having very small capacity, and plunger having the piston mounted thereto
IL213997A0 (en) Heteroatom- containing cyclic compounds, compositions comprising the same and uses thereof
EP2347962A4 (en) DISPOSABLE CONTAINER
PL2579928T3 (pl) Zespół napędowy, komponent napędu i urządzenie do podawania leku
ZA201002581B (en) Drought tolerant corn with reduced mycotoxin
AP2011005539A0 (en) Hypodermic syringe with retractable needle.
PL2419422T3 (pl) Pochodne imidazolidyno-2,4-dionu i ich zastosowanie jako leku
AP2011005697A0 (en) The 1-butyl-2-hydroxyaralkyl piperazine derivatives and the uses as anti-depression medicine thereof.
IT1395488B1 (it) Contenitore, relativo sbozzato e metodo per realizzare detto contenitore.
Yang Suggestion on Green Food Labeling
蒋涵毅 CAVDY
伊地知裕貴 niha
GB201101378D0 (en) One piece immediate load cylindrical dental implant., with angulated abutment